The double-blind, placebo-controlled phase 3 THRIVE-AA1 (NCT04518995) and THRIVE-AA2 (NCT04797650) trials in patients with severe alopecia areata (AA) evaluated the efficacy of deuruxolitinib in patients with ≥50% scalp hair loss (as measured by the Severity of Alopecia Tool, SALT). The trials’ primary endpoint, a SALT score ≤20 at week 24, was achieved by 31% of participants in the deuruxolitinib 8 mg twice-daily group, compared with 0.8% in the placebo group. The objective of the current post-hoc analysis was to examine the change in patient-reported hair satisfaction over 24 weeks in adult patients with AA who responded to deuruxolitinib 8 mg twice daily in a pooled analysis of the THRIVE-AA1 and THRIVE-AA2 trial [1].
Most participants had very significant hair loss. In both studies, 31.0% of participants randomised to deuruxolitinib achieved a SALT score ≤20 at week 24 and were included in the current analysis. The shift in hair satisfaction among responders to deuruxolitinib was assessed in the 5-point Hair Satisfaction Patient Reported Outcome (SPRO) scale.
By week 24, 95.7% of participants treated with deuruxolitinib who were initially dissatisfied with their hair reported satisfaction (P<0.0001). This shift occurred progressively. “As early as week 12, we saw impressive results: 79% of participants flipped from very dissatisfied to satisfied or very satisfied,” said Dr Paradi Mirmirani (Kaiser Permanente Vallejo Medical Center, CA, USA). No participants in the placebo group achieved similar outcomes.
These findings underscore the efficacy of deuruxolitinib in not only promoting hair regrowth but also improving patients’ overall satisfaction with their appearance.
- Mirmirani P. Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials. FC04.04, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support was provided by Dr Susanne Kammerer
Posted on
Previous Article
« Familial hidradenitis suppurativa associated with higher risk for metabolic disease Next Article
JAK1 inhibitor shows promising long-term efficacy in PN »
« Familial hidradenitis suppurativa associated with higher risk for metabolic disease Next Article
JAK1 inhibitor shows promising long-term efficacy in PN »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
August 26, 2019
Management strategies for drug-induced mucositis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com